Circulating donor-derived cell-free DNA: a true biomarker for cardiac allograft rejection?

Kevin P. Daly¹,²

¹Transplant Research Program & Department of Cardiology, Boston Children’s Hospital, Boston, MA 02115, USA; ²Department of Pediatrics, Harvard Medical School, Boston, MA 02115, USA

Correspondence to: Kevin P. Daly, MD. Transplant Research Program, And the Department of Cardiology, Boston Children’s Hospital, 300 Longwood Avenue, Boston, MA 02115, USA. Email: kevin.daly@childrens.harvard.edu.

Submitted Jan 22, 2015. Accepted for publication Jan 26, 2015.
doi: 10.3978/j.issn.2305-5839.2015.01.35
View this article at: http://dx.doi.org/10.3978/j.issn.2305-5839.2015.01.35

Heart transplantation remains a lifesaving therapy for adults and children with end-stage heart disease. Since the first heart transplant was performed in 1967, advances in peri-operative care and long term immunosuppression have dramatically improved post-transplant outcomes (1). Currently, adult recipients can expect a median allograft survival of greater than 10 years and infant recipients can expect a median allograft survival that is greater than 20 years (2,3). Beginning with the first transplant, detection of acute allograft rejection was of paramount concern. In a letter to Dr. Christiaan Barnard dated December 4, 1967 that is on display in the Heart of Cape Town Museum, Dr. Norman Shumway suggested an early biomarker. He wrote, “Be certain to watch the R-wave of the EKG during the next several weeks for indices of rejection. It appears to be the earliest herald of important graft invasion.” Since 1967, many advances have improved the precision with which cardiac allograft rejection is diagnosed, allowing the clinician to balance the competing risks of rejection, infection, and drug side effects. In addition, our ability to prevent rejection with calcineurin inhibitors, proliferation signal inhibitors, anti-proliferatives, and cytolytic cell therapy has dramatically improved outcomes (1-3). Diagnostic advances have included the development of a minimally invasive technique to obtain endomyocardial biopsy samples by Dr. Philip Caves, standardization of pathologic grading of acute cellular rejection (ACR) in 1990 and 2004 (4), standardization of pathologic grading of antibody mediated rejection (AMR) in 2013 (5), and the development of a clinically validated gene-expression profiling test to modulate biopsy screening frequency (6).

In their original research article entitled “Circulating Cell-Free DNA Enables Noninvasive Diagnosis of Heart Transplant Rejection,” De Vlaminck et al. (7) describe the performance characteristics of circulating cell-free donor-derived DNA (cfDNA) as a diagnostic test for ACR and AMR in a prospective cohort of pediatric and adult heart transplant recipients. The study leverages the dramatic decrease in cost of deep DNA sequencing technology to identify the proportion of circulating DNA that is donor derived in serially collected plasma samples. The authors demonstrate a good understanding of the limitations of the Illumina platform for deep DNA sequencing. By comparing loci known to be similar between donors and recipients, the authors were able to identify the baseline rate for incorrect sequence calls, eliminate loci with high error rates, and correct for the baseline error rate in the final analysis. Given the low fraction of donor derived DNA, errors in sequence calls at discrepant (informative) loci would be expected to result in a disproportionately high number of donor DNA calls, thus correcting for baseline error rate is of considerable importance in reducing the potential for false positive results. An alternative approach taken by other groups is to model the minor allele frequency for informative loci as a binomial distribution and define the cfDNA fraction as the frequency peak from the model (8). After developing the test methodology, the authors then demonstrate that the cfDNA fraction is elevated on post-transplant day 1, that the cfDNA fraction rapidly drops to baseline with a half-life of 2.4 days, and that a low sustained cfDNA baseline of 0.06%±0.11% is reached within the study cohort by 1 week post-transplantation.
Threshold selection and test performance characteristics

While most of the study methodology is strong, the authors do not report how the cutoff threshold for cfdDNA fraction was selected. Thresholds for a quantitative test can be set to maximize sensitivity, specificity or area under the receiver operating characteristic curve. It is not clear which, if any, of these outcomes was maximized with the chosen cutoff of 0.25%. In addition, a given study cohort is prone to sampling error when compared to the overall population of heart transplant recipients. This can lead to selection of a cutoff value with overly optimistic performance characteristics. To deal with this issue, data is usually either divided into training and validation sets or statistical methods, such as cross-validation, are used to account for this concern.

Developing a diagnostic test for rejection is complicated by the relatively low event rate in the current era for ACR and AMR. Reviewing our own institutional data, the rejection rate is approximately 2 rejection episodes per 100 patient years of follow-up. Our biopsy protocol calls for up to 9 biopsies in the first post-transplant year. As a result of a large denominator, only 3.2% of biopsies performed at our center in 2012 were classified as ACR 2R/3R or AMR. Using the reported cfdDNA test performance characteristics (sensitivity of 58% and specificity of 93%) and a rejection rate of 3.2% of tests, the positive predictive value (PPV) of the cfdDNA test is only 30.5% and the negative predictive value (NPV) is 97.6% (Table 1). With such a low event rate, nearly any diagnostic test would struggle to provide a perfect classification of rejection. As can be seen with the table, a higher event rate would increase the PPV significantly while hurting the NPV as well. Depending upon cost and ease of use, it is quite possible that the cfdDNA test will be used more frequently than endomyocardial biopsy. Assuming that the event rate for rejection will remain constant and the number of cfdDNA screens is doubled, the PPV will decrease even further (to 18%).

Due to the low event rate, a diagnostic strategy which first involves a screening test, followed by a confirmatory test is most appropriate. The CARGO II study provided clinicians with a gene-expression profile based score cutoff that has a NPV >99% (9). By setting the diagnostic cut-off such that NPV was optimized, the risk that clinical rejection will be missed is significantly lowered. By screening in this way the majority of the biopsies performed will still be negative for rejection, however the overall number of biopsies can be reduced approximately 3-fold without any change in clinical outcomes (6). While the IMAGE study demonstrated that shifting from a protocol biopsy schedule to a “for-cause” biopsy practice pattern in conjunction with gene-expression profiling yielded similar clinical outcomes, it failed to test the hypothesis that standard clinical assessments and a “for-cause” biopsy protocol triggered by clinician assessment, ECG, and echocardiography may have yielded the same results (10).

Physiologic relevance or “The Sniff Test”

cfdDNA fraction is appealing as a biomarker as it may

| Table 1 cfdDNA test performance characteristics modeling for different theoretical rejection rates and rejection screening frequencies |
|--------------------------------------------------|--------------------------------------------------|--------------------------------------------------|--------------------------------------------------|--------------------------------------------------|--------------------------------------------------|--------------------------------------------------|--------------------------------------------------|--------------------------------------------------|
| Characteristics                                | Assuming a cfdDNA testing performed at current biopsy frequency | Assuming a 2-fold increase in cfdDNA relative to current biopsy frequency |
| True positive rate                             | 0.032 | 0.050 | 0.100 | 0.150 | 0.200 | 0.016 | 0.025 | 0.050 | 0.075 | 0.100 |
| True negative rate                             | 0.968 | 0.950 | 0.900 | 0.850 | 0.800 | 0.984 | 0.975 | 0.950 | 0.925 | 0.900 |
| False negative rate                            | 0.023 | 0.036 | 0.072 | 0.109 | 0.145 | 0.012 | 0.018 | 0.036 | 0.054 | 0.072 |
| False positive rate                            | 0.073 | 0.072 | 0.068 | 0.064 | 0.060 | 0.074 | 0.073 | 0.072 | 0.070 | 0.068 |
| PPV                                            | 0.305 | 0.412 | 0.596 | 0.701 | 0.769 | 0.178 | 0.254 | 0.412 | 0.519 | 0.596 |
| NPV                                            | 0.977 | 0.963 | 0.926 | 0.887 | 0.847 | 0.988 | 0.982 | 0.963 | 0.945 | 0.926 |

Using a 0.25% cut-off for cfdDNA, De Vlaminck et al. (7) reported a sensitivity of 0.58 and specificity of 0.93 when comparing patients with acute cellular rejection grades 2R or 3R or antibody mediated rejection to those without rejection (Grade 0). In the right half of the table, we have assumed that cfdDNA tests are sent twice as often as we currently perform biopsies. Assuming that the baseline rate of rejection does not change, the true positive rate decreases affecting the PPV and NPV. cfdDNA, cell-free donor-derived DNA; PPV, positive predictive value; NPV, negative predictive value.
prove to be proportional to the degree of myocardial injury sustained during the rejection injury and repair response. As a quantitative test which can be trended non-invasively over time, it may also serve as a measure of therapeutic response. The paper by De Vlaminck et al. (7) presents data on several individual patients with rejection. While the cfDNA fraction trended down in each case, it did not return to baseline. The authors elegantly demonstrate that cfDNA fraction is high at the time of transplant, presumably due to ischemia reperfusion injury, but that it rapidly comes down to the baseline by the end of the first week. Since the cfDNA fraction remains elevated after treatment for rejection, this suggests that allograft injury/rejection is ongoing and/or that treatment is sub-optimal. Perhaps it is overly optimistic to assume that targeted anti-rejection treatment is able to acutely halt the rejection response in most cases when, in fact, myocardial injury may actually be an ongoing process following the acute rejection event. Studies which address patients with “recurrent rejection” may actually be identifying patients with persistent rejection and a waxing and waning clinical response to therapy (11,12). One could hypothesize that the rate at which cfDNA fraction returns to baseline will correlate with the development of allograft failure or dysfunction. If that is borne out in future studies, then cfDNA may serve as a viable proxy for treatment response, with persistently elevated levels of cfDNA indicating a need for intensification of anti-rejection therapy.

While biomarkers can be useful without developing a nuanced understanding of their role in pathophysiology, it would be helpful to understand the cellular source of the cfDNA. Cardiomyocytes do not divide rapidly and have a low proportion of DNA relative to their total cellular content. The endothelium is the primary target of the rejection response and has a relatively high DNA content (13). It is reasonable to hypothesize that a substantial portion of the cfDNA derives from the allograft endothelium when it is damaged, and subsequently repaired, during the rejection process. Endothelial repair occurs both from local proliferation of endothelial cells and recruitment of recipient endothelial progenitor cells from the circulation. This results in formation of a chimeric vascular endothelium over time within the allograft (14). As a result of this phenomenon, cfDNA may become less sensitive in the late post-transplant period after a greater number of recipient endothelial progenitor cells are incorporated within the allograft endothelium. In addition, measurement of the total circulating cell-free DNA content must be incorporated as a quality control. Since the cfDNA is reported as a percentage of total cell-free DNA, it is possible that increased amounts of total cell-free DNA could dilute the donor specific content and falsely skew the results. Such a scenario was recently reported in a transplant patient with sepsis (8).

Prior probabilities and the Bayesian approach to biomarker studies

Clinicians are taught throughout their medical training to take a Bayesian approach to diagnostic and treatment decisions by constantly modifying the prior probability of disease based on new information from multiple sources. Our analysis methods for biomarker studies rarely take an integrative Bayesian approach but instead rely upon comparison of the novel biomarker to a “gold standard” diagnostic test. In reality, the rejection event rates reported in clinical studies represent an average event rate for the study population. Depending upon time since transplant, levels of immunosuppression, presence of donor specific antibodies, presence of heart failure symptoms, appearance of the echocardiogram, and assessment of patient compliance, the pre-test probability for rejection will vary substantially for an individual patient (10,15). A more nuanced understanding about when diagnostic tests can meaningfully influence the probability of rejection is what is most important. Maximizing or changing diagnostic test cutoff thresholds based on the pre-test probability would be tremendously helpful to the heart transplant clinician. The adult cardiology community has performed this type of analysis effectively for treatment of coronary artery disease. Using tools readily available to the primary care clinician, 10-year risk of coronary artery disease is determined (16). This baseline risk then informs primary prevention treatment strategies. When patients present with an acute coronary syndrome, the prior probability of coronary artery disease helps determine which diagnostic tests are utilized to shift those probabilities and guide treatment decisions (17).

While pathological grading of endomyocardial biopsies has remained the gold standard in assessing biomarkers of rejection in heart transplant recipients, the biopsy serves as one more diagnostic test which modifies the prior probability of rejection. In a patient with a low likelihood of rejection, a biopsy which barely qualifies as an ACR 2R may not clinch the diagnosis of rejection. Conversely, patients can present with hemodynamic compromise and a compelling clinical rejection syndrome despite low
rejection grades on biopsy. For example, when rejection with hemodynamic compromise was examined in a pediatric heart transplant cohort, one-third of biopsies were graded as ACR 0R or 1R (15). In addition, despite improved ability to diagnose AMR, biopsy negative rejection continues to be a recognized phenomenon in heart transplant recipients with LV dysfunction (18). Multiple studies have demonstrated that the intraobserver variability between pathologists for grading endomyocardial biopsies is high in blinded comparisons (19). However, in the real world pathologists do not function as a core lab, divorced from clinical information or the prior probability of rejection. When a pathologist is deciding whether to call a marginal biopsy a 1R or a 2R, the indication for the biopsy, the center’s clinical protocols, and other clinical information, have the potential to bias the final biopsy grade.

Comparing new diagnostic tests to an imperfect gold standard introduces uncertainty into the estimates of test performance. Mengel et al. (20) have pointed out that molecular analysis of endomyocardial biopsy specimens and correlation of findings with clinically relevant rejection outcomes allows for refinement of the gold standard and increases the reliability of novel diagnostic test performance estimates. The heart transplant community has to take a creative and pragmatic approach to solve this problem. When designing comprehensive rejection biomarker studies, the outcome variable should be strictly defined but not limited to pathological endomyocardial biopsy grade. A carefully defined Bayesian algorithm or composite rejection score for classifying patients as rejectors and non-rejectors should outperform pathological grading of endomyocardial biopsies specimens alone as a study outcome variable. Only then will studies be able to discover and validate biomarkers that are most predictive of clinically meaningful rejection and poor patient outcomes.

Conclusions
Cell-free donor-specific DNA is an intriguing non-invasive biomarker for ACR and AMR in heart transplant patients. The study by De Vlaminck et al. is an important early step in understanding the performance characteristics when compared to pathologic diagnosis of ACR and AMR by endomyocardial biopsy (7). It will be vital to validate that the performance characteristics hold up in a larger cohort of heart transplant recipients and to demonstrate that clinical use of cfdDNA improves the care and outcomes for heart transplant recipients. Further study is also necessary to determine if cfdDNA fraction may provide independent clinical prognostic information and if cfdDNA can be used to monitor therapeutic response to anti-rejection therapy. It is time for our community to take a more integrative Bayesian approach to the definition of rejection outcome measures in biomarker studies and to study how new diagnostic tests can complement routine clinical care, rather than to replace it.

Acknowledgements

Funding: Dr. Daly has been supported by NIH grants L40 HL110356, T32 HL07572, and K12 HD052896-06, the Alexia Clinton Research Fund, and the Boston Children’s Hospital Cardiac Transplant and Education Fund.

Disclosure: The author declares no conflict of interest.

References


Cite this article as: Daly KP. Circulating donor-derived cell-free DNA: a true biomarker for cardiac allograft rejection? Ann Transl Med 2015;3(4):47. doi: 10.3978/j.issn.2305-5839.2015.01.35